Patents Examined by Devang Thakor
-
Patent number: 9101537Abstract: Compositions comprising electro-activated aqueous solutions and methods for the prevention and treatment of dysfunctional cardiovascular conditions are provided.Type: GrantFiled: July 24, 2009Date of Patent: August 11, 2015Assignee: REVEN PHARMACEUTICALS, INC.Inventors: Henk Van Wyk, Mariette Van Wyk, Trace Krebs, Peter Lange, Brian Denomme, Michael A. Volk
-
Patent number: 9089602Abstract: Compositions comprising electro-activated aqueous solutions and methods for the prevention and treatment of dysfunctional cardiovascular conditions are provided.Type: GrantFiled: November 21, 2014Date of Patent: July 28, 2015Assignee: REVEN PHARMACEUTICALS, INC.Inventors: Henk Van Wyk, Mariette Van Wyk, Trace Krebs, Peter Lange, Brian Denomme, Michael A. Volk
-
Patent number: 9089511Abstract: Compositions comprising electro-activated aqueous solutions and methods for the prevention and treatment of dysfunctional cardiovascular conditions are provided.Type: GrantFiled: November 21, 2014Date of Patent: July 28, 2015Assignee: REVEN PHARMACEUTICALS, INC.Inventors: Henk Van Wyk, Mariette Van Wyk, Trace Krebs, Peter Lange, Brian Denomme, Michael A. Volk
-
Patent number: 9044038Abstract: The present invention provides a technique for improving the sweetness of stevia extract. A composition having an excellent sweetness quality can be obtained by combining rebaudioside A, which is a main sweetness component of stevia extract, with mogroside V, which is a main sweetness component of siraitia grosvenorii extract, at a weight ratio of 95:5 to 60:40. By using the mixture described above as a sweetener, favorable sweetness can be imparted to various products, such as foods, medicines or quasi drugs.Type: GrantFiled: November 12, 2008Date of Patent: June 2, 2015Assignee: SAN-EI GEN F.F.I., INC.Inventors: Koji Yoshinaka, Masanori Mie, Maki Yamamoto, Hiroshige Ueno, Tetsuya Tokumura, Takeshi Aya
-
Patent number: 9017714Abstract: A nerve regeneration-inducing tube is provided which is excellent in cell growth property, resistance to pressure, shape recovery property, and anti-kink property in a nerve regeneration-inducing tube where a collagen solution is applied on the outer surface of a tubular body woven with ultrafine fiber comprising biodegradable and bioabsorbable polymer while collagen is filled in the inner area of the tubular body. The nerve regeneration-inducing tube has a degradation speed which is adjusted so as to make it suitable for the connection of nerve gaps of more than 40 mm. The nerve regeneration-inducing tube includes collagen coated on the outer surface of a tubular body woven with fiber bundles where plural ultrafine fibers comprising a biodegradable and bioabsorbable polymer are bundled. The tubular body mostly comprises a first polymer which is biodegradable and bioabsorbable and a second polymer which has higher biodegradability and bioabsorbability than those of the first polymer.Type: GrantFiled: December 25, 2008Date of Patent: April 28, 2015Assignee: Toyo Boseki Kabushiki KaishaInventors: Fumihiko Kajii, Hidenori Tanaka, Susumu Kashiwabara, Yuta Kawakatsu
-
Patent number: 9011885Abstract: The use, as a dermatological or cosmetic medicament, of compounds capable of transiently interacting with the AhR receptor (aryl hydrocarbon receptor) as agents for modulating skin functions such as sebaceous function, skin healing, skin atrophy termed “dermatoporosis”, estrogen deprivation and defense against infection, without inducing other toxic effects of the TCDD type. The compounds that interact with the AhR receptor are chosen in that they have a metabolism favorable to the dissociation of these effects, in particular by virtue of in situ production from a precursor and/or metabolization modulated in situ.Type: GrantFiled: July 30, 2014Date of Patent: April 21, 2015Assignee: Thesan Pharmaceuticals, Inc.Inventor: Jean Hilaire Saurat
-
Patent number: 8961932Abstract: A method for interrogating the microcirculation of a subject for use in characterizing function in health and disease, monitor changes in microcirculation over time, and identify responses in microcirculation to potentially harmful or beneficial interventions. The method includes delivering a study agent to a study surface for trans-surface delivery to the microvasculature of the subject and monitoring the microvasculature of the subject in the area of the study surface. A system is also provided which includes a micro-patch for delivery of study agent to a study surface for trans-surface delivery to the microvasculature of the subject and a monitoring probe for monitoring the microvasculature of the subject in the area of the study surface.Type: GrantFiled: March 31, 2008Date of Patent: February 24, 2015Inventor: David G. Silverman
-
Patent number: 8956601Abstract: The invention relates to pharmaceutical compositions and formulations comprising polymeric myrcene. More particularly, the invention relates to compositions comprising an isolated fraction of polymeric myrcene in a hydrophobic carrier and formulations which maintain the biological activity of the active polymer.Type: GrantFiled: March 4, 2010Date of Patent: February 17, 2015Assignee: Regenera Pharma Ltd.Inventor: Zadik Hazan
-
Patent number: 8932610Abstract: A pharmaceutical otic sterile preservative-free composition in the form of a clear aqueous solution comprising 0.01-0.10% (w/v) of Fluocinolone Acetonide, optionally accompanied by 0.1-0.8% of Ciprofloxacin or a pharmaceutically acceptable salt thereof, a nonionic surfactant, a tonicity adjusting agent and a viscosity increasing agent. It is useful for the prevention and/or treatment of otic inflammation, optionally accompanied by bacterial infection, and for administration from single-use containers.Type: GrantFiled: March 24, 2010Date of Patent: January 13, 2015Assignee: Laboratorios Salvat, S.A.Inventors: Jaume Ruiz I Pol, Francisca Izquierdo Torres
-
Patent number: 8889155Abstract: The present invention provides a stable gel composition for mycosis treatment, with increased absorption and permeation of (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidin -1-yl)-1-(1H-1,2,4-triazol-1-yl)-butan-2-ol into a target site (skin and nail). The gel composition for mycosis treatment, comprises (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidin-1-yl) -1-(1H-1,2,4-triazol-1-yl)-butan-2-ol or an acid addition salt thereof, a lower alcohol, a polyhydric alcohol and a gel-forming polymer. The gel composition of the present invention increases permeation of the above compound into a target site and into the nail. The gel composition of the present invention allows the drug to be directly and rapidly absorbed and permeated into a target site in a constant manner, for mycosis treatment, particularly onychomycosis treatment.Type: GrantFiled: December 28, 2007Date of Patent: November 18, 2014Assignee: Kaken Pharmaceutical Co., Ltd.Inventors: Tomohiro Okumura, Akiko Ochiai, Keizo Sakuda, Yoshiyuki Tatsumi
-
Patent number: 8778398Abstract: The present invention provides a solid immediate release dosage form adapted for oral administration of GHB. The solid immediate release dosage form includes an immediate release formulation comprising a relatively high weight-percentage of GHB with a bioavailability similar to that of a liquid GHB dosage form.Type: GrantFiled: May 4, 2010Date of Patent: July 15, 2014Assignee: Jazz Pharmaceuticals, Inc.Inventors: Andrea Marie Rourke, Maura Patricia Murphy, James Frederick Pfeiffer, Clark Patrick Allphin, Alya Khan McGinlay
-
Patent number: 8778399Abstract: Tablets and other objects are film coated by including in the tablet a film-forming polymer that is activated upon contact with an activating amount of liquid. The film-forming polymer, e.g., a cellulosic ether, is homogeneously mixed with the other ingredients of the tablet, shaped into any desirable form, loaded into a conventional coating apparatus, and sprayed or foamed with an activating amount of fluid, e.g., water, alcohol, etc., and dried. This coating process eliminates potential problems such as spray nozzle clogging, inappropriate coating fluid viscosity, and the inability to properly atomize the coating fluid. This coating process does not impart any appreciable weight or thickness gain to the tablet.Type: GrantFiled: June 2, 2008Date of Patent: July 15, 2014Assignee: Dow Global Technologies LLCInventors: Paul J. Sheskey, Colin M. Keary
-
Patent number: 8771735Abstract: The present invention provides a pharmaceutical composition, presented as a solid unit dosage form adapted for oral administration of sodium oxybate. The preferred unit dosage form is a tablet comprising a relatively high weight-percentage of sodium oxybate, in combination with a relatively small weight-percentage of total excipients. This permits the tablets to contain/deliver a pharmaceutically effective amount, e.g., about 0.5-1.5 g of sodium oxybate in each tablet with a delivery profile similar to that of the liquid form. The tablets are bioequivalent to the liquid form.Type: GrantFiled: November 4, 2008Date of Patent: July 8, 2014Assignee: Jazz Pharmaceuticals, Inc.Inventors: Andrea Rourke, Clark Allphin, Maura Murphy
-
Patent number: 8753621Abstract: Improved biodegradable and bioabsorbable BAB-block copolymers exhibiting reverse thermal gellation properties, and aqueous polymer compositions including the BAB-block copolymers, are provided. Methods of making the improved BAB-block copolymers and compositions including the same are also provided.Type: GrantFiled: September 20, 2010Date of Patent: June 17, 2014Assignee: Protherics Salt Lake City, Inc.Inventors: Kirk D. Fowers, Ramesh C. Rathi, Ai-Zhi Piao
-
Patent number: 8741319Abstract: The present invention relates to methods and compositions for reducing distress dysfunction, including emotional and physical distress. The invention entails co-administration of at least one Receptor Switcher and at least one Endorphin Enhancer. Additionally, at least one Synergistic Enhance and/or at least one Exogenous Opioid are also administered to enhance or prolong the therapeutic effects.Type: GrantFiled: November 5, 2013Date of Patent: June 3, 2014Assignee: Pondera Biotechnologies, Inc.Inventors: Steven Crain, William E. Crain, Stanley M. Crain, Michael Crain
-
Patent number: 8722065Abstract: The present invention discloses a novel tape preparation containing lidocaine at a high concentration. A tape preparation containing lidocaine at a high content, which has a lidocaine content of 10 w/w % or more, can be produced by using a lactic acid salt of lidocaine, while preventing the precipitation of a crystal of lidocaine.Type: GrantFiled: November 10, 2008Date of Patent: May 13, 2014Assignee: MEDRx Co., Ltd.Inventors: Masaki Ishibashi, Hidetoshi Hamamoto
-
Patent number: 8722094Abstract: A powdery porous carrier comprising a porous silicon-containing carrier is impregnated with a solution containing an organic solvent and an active ingredient hardly soluble in water, and the organic solvent is removed to give a solid dispersion having the active ingredient supported to the porous carrier without a treatment with a supercritical fluid. The porous silicon-containing carrier has a heating loss of not more than 4% by weight at a temperature of 950° C. for 2 hours (e.g., a spherical silicon-containing carrier such as a spherical porous silica). The porous silicon-containing carrier may be a spherical silica having a mean pore size of 10 to 40 nm and an oil absorption of 175 to 500 ml/100 g. A pharmaceutical composition (e.g., tablets, granules, or capsules) may be prepared from the solid dispersion and a pharmaceutically acceptable carrier.Type: GrantFiled: March 10, 2009Date of Patent: May 13, 2014Assignee: Aska Pharmaceutical Co., Ltd.Inventors: Kazushi Yoshida, Norimichi Okubo, Junichi Sakata, Hashime Kanazawa
-
Patent number: 8697096Abstract: Disclosed is a tape preparation comprising etodolac in an ionic liquid form, which has high transdermal absorbability. Etodolac is reacted with an organic amine compound to produce an ionic liquid of etodolac. By using the ionic liquid, it becomes possible to increase the transdermal absorbability of etodolac. Further for the purpose of enhancing the transdermal absorbability and the tissue penetration ability of an ionic solution of etodolac, the composition of an organic solvent system for the ionic solution of etodolac is investigated, and it is found that a mixed solvent of an alcohol and an ester (1:2 to 2:1) is suitable as the organic solvent. Still further, an appropriate adhesion force can be achieved by properly selecting a softening agent. In this manner, a tape preparation having good transdermal absorbability can be prepared.Type: GrantFiled: December 9, 2008Date of Patent: April 15, 2014Assignee: MEDRx Co., Ltd.Inventors: Hidetoshi Hamamoto, Yasushi Miwa
-
Patent number: 8691183Abstract: The present invention relates to a composition for the detection and the treatment of prostate cells and to methods for the diagnostic and therapeutic treatment of a human being using the composition according to the invention.Type: GrantFiled: February 8, 2011Date of Patent: April 8, 2014Assignee: Eberhard-Karls-Universitaet Tuebingen UniversitaetsklinikumInventor: Stefan Heckl
-
Patent number: 8685417Abstract: Encapsulation of and binding to pegylated bioactive molecules via functionalized comb, block, branched type polymers formed by nitroxide mediated controlled radical polymerization is disclosed.Type: GrantFiled: December 12, 2007Date of Patent: April 1, 2014Assignee: Arkema, Inc.Inventors: Scott C. Schmidt, Michael S. Mendolia, Peter A. Callais